TP53 and B-cell non-Hodgkin lymphoma: Since the EBV is an oncovirus and capable of helping infected cells survive by suppressing tumor suppressor p53-associated apoptosis through the p53 pathway [24], and EBV + B-cell-lymphoma is known to be vulnerable to MDM2 inhibition [25], we tested the treatment of these cells using the MDM2-inhibitor HDM201 which suppresses the binding of MDM2 to p53 [26] leading to p53 protein degradation.